X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ALEMBIC LTD - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ALEMBIC LTD TORRENT PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 45.8 56.2 81.4% View Chart
P/BV x 6.5 2.3 275.4% View Chart
Dividend Yield % 0.8 0.4 182.5%  

Financials

 TORRENT PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
ALEMBIC LTD
Mar-18
TORRENT PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,55072 2,152.8%   
Low Rs1,14434 3,373.2%   
Sales per share (Unadj.) Rs354.74.7 7,545.6%  
Earnings per share (Unadj.) Rs40.16.1 656.6%  
Cash flow per share (Unadj.) Rs64.26.2 1,028.3%  
Dividends per share (Unadj.) Rs14.000.20 7,000.0%  
Dividend yield (eoy) %1.00.4 275.2%  
Book value per share (Unadj.) Rs273.140.7 671.8%  
Shares outstanding (eoy) m169.22267.03 63.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.811.3 33.7%   
Avg P/E ratio x33.68.7 387.4%  
P/CF ratio (eoy) x21.08.5 247.3%  
Price / Book Value ratio x4.91.3 378.6%  
Dividend payout %34.93.3 1,066.1%   
Avg Mkt Cap Rs m227,89714,139 1,611.8%   
No. of employees `00014.7NA-   
Total wages/salary Rs m11,353207 5,473.7%   
Avg. sales/employee Rs Th4,083.0NM-  
Avg. wages/employee Rs Th772.3NM-  
Avg. net profit/employee Rs Th461.3NM-  
INCOME DATA
Net Sales Rs m60,0211,255 4,781.8%  
Other income Rs m2,988370 807.2%   
Total revenues Rs m63,0091,625 3,876.5%   
Gross profit Rs m13,493111 12,144.5%  
Depreciation Rs m4,08638 10,809.5%   
Interest Rs m3,0852 181,458.8%   
Profit before tax Rs m9,310442 2,107.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m01,212 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,52924 10,558.2%   
Profit after tax Rs m6,7811,630 416.1%  
Gross profit margin %22.58.9 254.0%  
Effective tax rate %27.25.4 501.0%   
Net profit margin %11.3129.8 8.7%  
BALANCE SHEET DATA
Current assets Rs m52,6231,867 2,818.4%   
Current liabilities Rs m52,022591 8,799.3%   
Net working cap to sales %1.0101.6 1.0%  
Current ratio x1.03.2 32.0%  
Inventory Days Days12094 126.9%  
Debtors Days Days7674 103.7%  
Net fixed assets Rs m85,0161,791 4,747.1%   
Share capital Rs m846534 158.4%   
"Free" reserves Rs m45,37610,324 439.5%   
Net worth Rs m46,22210,858 425.7%   
Long term debt Rs m41,11541 99,792.7%   
Total assets Rs m142,43211,591 1,228.9%  
Interest coverage x4.0260.9 1.5%   
Debt to equity ratio x0.90 23,441.7%  
Sales to assets ratio x0.40.1 389.1%   
Return on assets %6.914.1 49.2%  
Return on equity %14.715.0 97.7%  
Return on capital %14.215.2 93.4%  
Exports to sales %01.5 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA19 0.0%   
Imports (cif) Rs mNA263 0.0%   
Fx inflow Rs m14,58019 75,155.2%   
Fx outflow Rs m3,600264 1,364.5%   
Net fx Rs m10,980-244 -4,492.3%   
CASH FLOW
From Operations Rs m8,942236 3,792.1%  
From Investments Rs m-47,070-224 21,013.2%  
From Financial Activity Rs m34,174-27 -128,473.3%  
Net Cashflow Rs m-3,655-15 24,695.9%  

Share Holding

Indian Promoters % 71.5 64.0 111.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 0.2 3,510.0%  
FIIs % 12.6 9.7 129.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 26.1 33.7%  
Shareholders   26,511 54,701 48.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  IPCA LABS  

Compare TORRENT PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

ALEMBIC LTD Announces Quarterly Results (1QFY19); Net Profit Up 106.9% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, ALEMBIC LTD has posted a net profit of Rs 69 m (up 106.9% YoY). Sales on the other hand came in at Rs 445 m (up 50.4% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 13.3% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 13.3% YoY). Sales on the other hand came in at Rs 19 bn (up 36.2% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS